Galena Biopharma Initiates RELIEF Patient Registry for Abstral(R) (fentanyl)
*RELIEF:Rapid Evaluation of Lifestyle, Independence, and Elimination of
breakthrough cancer pain with Freedom from oral discomfort through the use
of Abstral® (fentanyl) Sublingual Tablets
*Galena debuts Abstral campaign at PAINWeek September 4-7, 2013 in Las
*Galena to generate sales revenue in 2013 with significant progress towards
Abstral® commercial launch in the fourth quarter.
PORTLAND, Ore., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma
(Nasdaq:GALE), a biopharmaceutical company commercializing and developing
innovative, targeted oncology treatments that address major unmet medical
needs to advance cancer care, today announced the initiation of the Company's
Institutional Review Board (IRB)-approved cancer patient registry study
entitled RELIEF: Rapid Evaluation of Lifestyle, Independence, and Elimination
of breakthrough cancer pain with Freedom from oral discomfort through the use
of Abstral® (fentanyl) Sublingual Tablets. RELIEF is a post-marketing
multicenter trial to assess Abstral for breakthrough cancer pain (BTcP) in
opioid-tolerant cancer patients.Abstral is available to patients and health
care professionals at pharmacies nationwide, and recruitment and enrollment
for the registry trial is underway.
RELIEF is a registry study to be completed by enrolled patients over a thirty
day period while using Abstral for treatment of their breakthrough cancer
pain.Approximately 2,500 patients are expected to enroll in the program.
Galena also announced the debut of Abstral's sales and marketing campaign at
the PAINWeek conference taking place September 4-7, 2013 in Las Vegas,
NV.With over 1,800 attendees, PAINWeek is one of the nation's largest pain
conferences for healthcare professionals with an interest in pain
management.Galena's commercial team is now fully staffed and on schedule for
a fourth quarter launch with senior level executives and a highly experienced
sales force.The Company's patient assistance and reimbursement program has
been implemented and is being accessedby patients across the country.
"With collaboration and support from the physician community, we are excited
to initiate our RELIEF trial and debut Abstral this week, which we believe is
the the best product in this class of drugs for patients suffering from
breakthrough cancer pain,"said Mark J. Ahn, President and CEO."Abstral's
product features, including its ease of use, and lack of product disposal
issues, make it an important treatment option for these patients.The RELIEF
registry is a critical initiative that will help assess the attributes of the
drug and provide a sizeable data set to support physicians who prescribe
Abstral. The initiation of our registry program ahead of our official launch
is an important first step in our overall commercial plan as the second half
of the year will be transformational for Galena, as we generate sales and
become a revenue producing organization."
RELIEF was developed with input from leading pain treatment specialists and is
intended to provide Galena with valuable insight from patients taking Abstral
by assessing a variety of characteristics including pain severity, ease of
use, patient satisfaction, and overall quality of life.Galena expects to
share the RELIEF results with physicians to provide relevant feedback as they
address the challenges in treating patients suffering from BTcP.
About Abstral® (fentanyl) Sublingual Tablets
Abstral® (fentanyl) Sublingual Tablets are an important treatment option for
inadequately controlled breakthrough cancer pain (BTcP) which impact 40%-80%
of cancer patients. Abstral is approved by the FDA, and is a sublingual (under
the tongue) fentanyl tablet indicated for the management of breakthrough pain
in patients with cancer, 18 years of age and older, who are already receiving,
and who are tolerant to, opioid therapy for their persistent baseline cancer
pain. The innovative Abstral formulation delivers the analgesic power and
increased bioavailability of micronized fentanyl in a more convenient
sublingual tablet which rapidly dissolves under the tongue in seconds,
provides rapid relief of breakthrough pain in minutes, and matches the
duration of the entire pain episode. Abstral is available through the
transmucosal immediate-release fentanyl (TIRF) Risk Evaluation and Mitigation
Strategy (REMS) program. For additional important safety information, see the
full Prescribing Information for Abstral available at www.abstral.com.
About Breakthrough Cancer Pain
Breakthrough cancer pain is defined as a transient exacerbation of pain that
occurs either spontaneously, or in relation to a specific predictable or
unpredictable trigger, despite relatively stable and adequately controlled
background pain.Breakthrough cancer pain occurs in 40-80 percent of patients
who are already receiving chronic, long-acting opioid pain management and yet
have episodes of severe tumor- and treatment-related cancer pain.Breakthrough
pain occurs frequently in these patients, particularly as they try to conduct
normal daily activities, with a mean number of episodes of 4 per day (average
range 1-14 per day) and a median duration of 30 minutes (range 1-240 minutes).
The wide range of time to relief of these severe pain episodes leads to high
levels of distress and impaired quality of life experienced by patients.
About Galena Biopharma
Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based
biopharmaceutical company commercializing and developing innovative, targeted
oncology treatments that address major unmet medical needs to advance cancer
care.For more information visit www.galenabiopharma.com.
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 relating to Galena's
expectations for commercialization of Abstral® and the development of Galena's
NeuVax™ product candidate.These forward-looking statements are subject to a
number of risks, uncertainties and assumptions, including the possibility that
Galena's commercialization of Abstral may be delayed or prove
unsuccessful.Galena's business and operations and the development of its
product candidates also are subject to the risks and uncertainties identified
under "Risk Factors" in Galena's Annual Report on Form 10-K for the year ended
December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended June
30, 2013 filed with the SEC.Actual results may differ materially from those
contemplated by these forward-looking statements. Galena does not undertake to
update any of these forward-looking statements to reflect a change in its
views or events or circumstances that occur after the date of this press
CONTACT: Remy Bernarda
Senior Director, Communications
Galena Biopharma, Inc.
Press spacebar to pause and continue. Press esc to stop.